SCHEMBL918875

SCHEMBL918875

CC(C)(C)C1=CCC(=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7797193 0.82 PPARG (0.32)
SCHEMBL401757 0.78
SCHEMBL21955629 0.68
SCHEMBL6577421 0.67
SCHEMBL8388914 0.62 PTPN1 (0.36)
SCHEMBL9706974 0.62
SCHEMBL30344962 0.62
SCHEMBL29478293 0.62
SCHEMBL7598535 0.62
SCHEMBL17441373 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-11571419-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2023-02-07 US disclosed
US-11197891-B2 Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith LANDOS BIOPHARMA, INC. (US) 2021-12-14 US disclosed
US-20210046070-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2021-02-18 US disclosed
US-10849895-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2020-12-01 US disclosed
US-20200261447-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2020-08-20 US disclosed
US-10682349-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2020-06-16 US disclosed
US-20200046694-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2020-02-13 US disclosed
US-20190160100-A1 THERAPIES WITH LANTHIONINE C-LIKE PROTEIN 2 LIGANDS AND CELLS PREPARED THEREWITH LANDOS BIOPHARMA, INC. (US) 2019-05-30 US disclosed
US-20160115153-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS BIOTHERAPEUTICS, INC. (US) 2016-04-28 US disclosed
US-9254272-B2 Resorcinol derivatives SUTTER WEST BAY HOSPITALS (US) 2016-02-09 US disclosed
US-20130209483-A1 CANNABIDINOID DERIVATIVES SUTTER WEST BAY HOSPITALS (US) 2013-08-15 US disclosed
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-20110009560-A1 ETHYLENICALLY UNSATURATED MONOMERS COMPRISING ALIPHATIC AND AROMATIC MOIETIES DOW GLOBAL TECHNOLOGIES INC. (US) 2011-01-13 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed
EP-0612783-B1 Cyanate resin composition and copper-clad laminate SUMITOMO CHEMICAL CO (JP) 1999-05-06 EP disclosed
US-5563237-A INCLUDES A BISMALEIMIDE HARDENER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-10-08 US disclosed
EP-0612783-A1 Cyanate resin composition and copper-clad laminate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1994-08-31 EP disclosed
WO-1993002074-A1 ALKOXYAMINO KETALS, THEIR PREPARATION AND INTERMEDIATE PRODUCTS THEREFOR, AND THEIR USE AS FUNGICIDES CHEMINOVA AGRO A/S (DK) 1993-02-04 WO disclosed